L'intérêt à découvert pour Walgreens Boots Alliance donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Walgreens Boots Alliance. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Walgreens Boots Alliance (NASDAQ:WBA) Stock, Rapport sur les intérêts à découvert

Walgreens Boots Alliance

Walgreens Boots Alliance is one of the largest retail pharmacy chains in the US, with over 8,000 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the US. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.

Walgreens Boots Alliance, Inc. - Common Stock

Walgreens Boots Alliance Inc

WisdomTree Trust WisdomTree Battery Value Chain and Innovation Fund

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
<h3 class="wp-block-heading">Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)</h3>
<ul>
<li>Dividend Yield: 11.79%</li>
<li>UBS analyst Kevin Caliendo maintained a Neutral rating and raised the price target from $9 to $10 on Oct. 17. This analyst has an accuracy rate of 73%.</li>
<li>Morgan Stanley analyst Erin Wright maintained an Underweight rating and cut the price target from $9 to $7 on Oct. 11. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: Walgreens agreed to $100 million settlement over alleged deceptive pricing of generic drugs.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111824&amp;t=be2bearmibe3na1">latest WBA news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18043410/image-178.png" alt="" class="wp-image-652534" style="width:653px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18043410/image-178.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18043410/image-178-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18043410/image-178-768x700.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">B&amp;G Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>)</h3>
<ul>
<li>Dividend Yield: 12.24%</li>
<li>Barclays analyst Brandt Montour maintained an Equal-Weight rating and cut the price target from $8 to $7 on Nov. 7. This analyst has an accuracy rate of 69%.</li>
<li>TD Cowen analyst Robert Moskow maintained a Sell rating and slashed the price target from $8 to $7.5 on Nov. 6. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On Nov. 5, B&amp;G Foods reported worse-than-expected third-quarter financial results and issued FY24 net sales guidance below estimates.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111824&amp;t=be2bearmibe3na1">latest BGS news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="866" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18043447/image-179.png" alt="" class="wp-image-652535" style="width:686px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18043447/image-179.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18043447/image-179-300x284.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18043447/image-179-768x726.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">The Kraft Heinz Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>)</h3>
<ul>
<li>Dividend Yield: 5.14%</li>
<li>Piper Sandler analyst Michael Lavery maintained an Overweight rating and cut the price target from $41 to $40 on Oct. 31. This analyst has an accuracy rate of 69%.</li>
<li>Mizuho analyst John Baumgartner maintained an Outperform rating and cut the price target from $43 to $41 on Oct. 31. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On Nov. 13, the company's board declared a regular quarterly dividend of 50 cents per share on its common stock.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111824&amp;t=be2bearmibe3na1">KHC stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="913" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18043535/image-180.png" alt="" class="wp-image-652536" style="width:648px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18043535/image-180.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18043535/image-180-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18043535/image-180-768x707.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure>
<a href="https://www.youtube.com/watch?time_continue=1&amp;v=pVF0O2lsEH4&amp;embeds_referring_euri=https%3A%2F%2Fwww.benzinga.com%2F">https://www.youtube.com/watch?time_continue=1&amp;v=pVF0O2lsEH4&amp;embeds_referring_euri=https%3A%2F%2Fwww.benzinga.com%2F</a>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
<a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">Read More: </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Wall Street's Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 5% Dividend Yields

In 2018, the International Brotherhood of Electrical Workers Local 38 Health and Welfare Fund and some consumers filed a proposed class action lawsuit against Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>).
The plaintiffs <a target="_blank" href="https://cases.justia.com/federal/district-courts/illinois/ilndce/1:2017cv02246/338055/91/0.pdf?ts=1520678017" rel="noreferrer noopener">alleged</a> that the retail pharmacy engaged in deceptive pricing practices through its Prescription Savings Club (PSC)—a program offering discounted prices on generic drugs for customers who pay without insurance.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41366045/walgreens-boots-alliance-analysts-expect-strategic-plans-will-boost-investor-confid" rel="noreferrer noopener">Walgreens Boots Alliance Analysts Expect Strategic Plans Will Boost Investor Confidence In 2025</a>
Plaintiffs claim these practices led Walgreens to inflate the &#8220;usual and customary&#8221; (U&amp;C) prices reported to health insurers and third-party payors, resulting in customers overpaying for generic drugs.
Reuters noted that Walgreens&nbsp;has agreed to pay $100 million to settle a proposed class action lawsuit.
Reuters cited a Walgreens spokesperson and noted that the company accepts no liability and maintains that these claims are without merit.
Walgreens introduced its Prescription Savings Club (PSC) in 2007, offering over 500 commonly prescribed generic medications at reduced prices: $5, $10, or $15 for 30-day supplies, and $10, $20, or $30 for 90-day supplies, depending on the drug&#8217;s tier. Enrollment in the PSC requires a yearly fee of $20 for individuals or $30 per family.
The complaint asserts that while Walgreens offered these lower PSC prices to cash-paying customers, it charged higher prices for the same drugs to customers using private insurance, Medicare, or Medicaid. According to the plaintiffs, Walgreens&#8217; PSC prices should have been reported as its U&amp;C prices.
Instead, by reporting higher-than-PSC prices as U&amp;C prices on reimbursement claims, Walgreens allegedly engaged in a hidden dual-pricing scheme for drugs listed under the PSC.
Price Action: At last check Tuesday, WBA stock was up 0.21% at $9.35 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/11/41739764/taiwan-semiconductor-faces-rising-energy-costs-potential-outages-threaten-production" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Faces Rising Energy Costs, Potential Outages Threaten Production</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

Legal

General

Walgreens Agrees To $100 Million Settlement Over Alleged Deceptive Pricing Of Generic Drugs

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
<h3 class="wp-block-heading">Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)</h3>
<ul>
<li>Dividend Yield: 10.69%</li>
<li>Jefferies analyst Brian Tanquilut maintained a Hold rating and cut the price target from $19 to $9 on Oct. 23. This analyst has an accuracy rate of 63%.</li>
<li>UBS analyst Kevin Caliendo maintained a Neutral rating and raised the price target from $9 to $10 on Oct. 17. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Oct. 24, Walgreens and Veeva Systems entered into long-term partnership to enhance patient outcomes.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103024&amp;t=be2bearmibe3na1">latest WBA news.</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30075758/image-309.png" alt="" class="wp-image-621537" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30075758/image-309.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30075758/image-309-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30075758/image-309-768x708.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">The Kraft Heinz Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>)</h3>
<ul>
<li>Dividend Yield: 4.60%</li>
<li>Stifel analyst Matthew Smith downgraded the stock from Buy to Hold and lowered the price target from $40 to $38 on Oct. 25. This analyst has an accuracy rate of 61%.</li>
<li>Wells Fargo analyst Chris Carey maintained an Equal-Weight rating and raised the price target from $34 to $35 on Aug. 1. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On Oct. 30, Kraft Heinz posted mixed results for the third quarter.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103024&amp;t=be2bearmibe3na1">latest KHC news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="897" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30075948/image-310.png" alt="" class="wp-image-621547" style="width:631px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30075948/image-310.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30075948/image-310-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30075948/image-310-768x724.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure>
<h3 class="wp-block-heading">Flowers Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLO#NYSE">FLO</a>)</h3>
<ul>
<li>Dividend Yield: 4.36%</li>
<li>DA Davidson analyst Brian Holland maintained a Neutral rating and raised the price target from $24 to $25 on May 17. This analyst has an accuracy rate of 65%.</li>
<li>Deutsche Bank analyst Steve Powers maintained a Hold rating and raised the price target from $22 to $23 on May 9. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: Flowers Foods will report its third quarter financial results on Friday, Nov. 8.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103024&amp;t=be2bearmibe3na1">trend in FLO stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30080028/image-311.png" alt="" class="wp-image-621552" style="width:635px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30080028/image-311.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30080028/image-311-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30080028/image-311-768x705.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41599928/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-for-october">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio For October</a></li>
</ul>

Wall Street's Most Accurate Analysts Spotlight On 3 Risk Off Stocks Delivering High-Dividend Yields

Uber Eats (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) today announced the arrival of a new initiative to expand access to more nutritious food for millions of Americans. Available now, Uber Eats is accepting SNAP (Supplemental Nutrition Assistance Program) EBT (Electronic Benefits Transfer) payments, starting with the regional grocery banners Albertsons, Safeway, Jewel-Osco and Vons as well as Walgreens locations nationwide and Duane Reade stores exclusively in New York.

UBER

Uber Eats Now Accepting SNAP EBT Nationwide With Albertsons, Safeway, Jewel-Osco and Vons As Well As Walgreens Locations Nationwide And Duane Reade Stores Exclusively In New York

VEEV

Walgreens And Veeva Systems Enter Long-Term Partnership To Enhance Patient Outcomes; Walgreens Gains Access To Veeva Data Cloud And Clinical Platform To Better Serve Life Sciences Industry

In the preceding three months, 10 analysts have released ratings for Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.65, a high estimate of $16.00, and a low estimate of $7.00. Highlighting a 20.22% decrease, the current average has fallen from the previous average price target of $13.35. 
<img src="https://www.benzinga.com/files/images/story/2024/1729713717_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Walgreens Boots Alliance. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Charles Ryhee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$8.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$10.00</td>
<td>$7.50</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Charles Ryhee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$7.50</td>
<td>$11.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Walgreens Boots Alliance. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Walgreens Boots Alliance compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Walgreens Boots Alliance's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Walgreens Boots Alliance's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WBA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Walgreens Boots Alliance analyst ratings.</a>
<h2>Unveiling the Story Behind Walgreens Boots Alliance</h2>
Walgreens Boots Alliance is one of the largest retail pharmacy chains in the US, with over 8,000 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the US. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.
<h3>A Deep Dive into Walgreens Boots Alliance's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Walgreens Boots Alliance showcased positive performance, achieving a revenue growth rate of 6.0% as of 31 August, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -8.0%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Walgreens Boots Alliance's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -24.95%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Walgreens Boots Alliance's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -3.66%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 3.14, Walgreens Boots Alliance faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Walgreens Boots Alliance: 10 Analysts Share Their Views

Jefferies analyst Brian Tanquilut maintains Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) with a Hold and lowers the price target from $19 to $9.

Jefferies Maintains Hold on Walgreens Boots Alliance, Lowers Price Target to $9

WIIM

Walgreens Boots Alliance shares are trading lower after TD Cowen cut its price target on the stock from $16 to $14.

Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) announced on Tuesday that it will begin offering Pharmacy Delivery services for both new prescriptions and medication refills, intensifying competition in <a href="https://www.benzinga.com/news/earnings/24/10/41399396/pharmacy-retailer-cvs-health-backs-away-from-annual-forecast-names-new-ceo">the pharmacy retail space.</a>
The Details: Walmart is <a href="https://www.benzinga.com/pressreleases/24/10/b41449460/accelerating-convenience-walmart-launches-nationwide-same-day-pharmacy-delivery-helping-customers-">rolling out</a> Pharmacy Delivery in six states and expects the new service to expand to 49 states by the end of January 2025. Walmart+ members will receive free delivery on Pharmacy Delivery, and non-Walmart+ members will pay the standard delivery charge of $9.95. 
"​​Our extensive footprint across the nation combined with our deep expertise in pharmacy uniquely positions us to make a profound impact in the communities we serve,&#8221; said Kevin Host, senior vice president of Pharmacy at Walmart U.S.
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41431993/amd-to-benefit-from-ai-competitive-arms-race-goldman-sachs"> AMD To Benefit From AI &#8216;Competitive Arms Race&#8217;: Goldman Sachs</a>
Why It Matters: Walmart's Pharmacy Delivery is another blow to struggling pharmacy retailers CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) who offer comparable delivery services. The retail giant's move into prescription delivery could lead to market share losses for CVS and Walgreens who already compete with Amazon.com, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) <a href="https://www.benzinga.com/news/large-cap/24/10/41270285/amazon-pharmacy-to-double-service-areas-offer-same-day-medication-delivery">same-day prescription delivery</a> in some areas. Amazon has plans to expand its pharmacy delivery to 20 more U.S. cities by 2025.
CVS and Walgreens have said <a href="https://www.benzinga.com/news/earnings/24/10/41405992/elevance-cvs-unitedhealth-struggle-with-rising-medical-costs-after-covid-19-medicaid-policy-ends">they are struggling</a> with falling reimbursement rates for prescription drugs. Both retail chains have shuttered store locations and announced cost-cutting measures as part of corporate turnaround strategies. 
The stores may face increased pressure on profit margins and staffing needs due to increased competition from Walmart. Both retailers have already reduced pharmacy hours in response to staffing challenges, which have been partly driven by the need to support delivery services.&nbsp;
WMT, CVS, WBA, AMZN Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Walmart shares are up 0.67% at $81.35, CVS shares are down 1.74% at $57.16, Walgreens shares are down 4.64% at $9.96 and Amazon shares are up 0.42% at $189.87 at the time of publication Tuesday.
Read Also:&nbsp;
<ul>
<li>&nbsp;<a href="https://www.benzinga.com/news/24/10/41418987/nuclear-energy-stocks-are-hot-heres-a-list-of-tickers-to-watch">Nuclear Energy Stocks Are Hot: Here&#8217;s A List Of Tickers To Watch</a></li>
</ul>
Photo: Jeff Bukowski/Shutterstock.com

Movers

AMZN

Walmart Launches Same-Day Pharmacy Delivery, Upping Competition For CVS, Walgreens

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham raised Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) price target from $600 to $700. Needham analyst Joshua Reilly maintained a Buy rating. Tyler Technologies shares closed at $586.77 on Monday. <a href="https://www.benzinga.com/quote/TYL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Bernstein cut the price target for Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) from $135 to $112. Bernstein analyst Harshita Rawat downgraded the stock from Outperform to Market Perform. Global Payments shares closed at $99.98 on Monday. <a href="https://www.benzinga.com/quote/GPN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised the price target for Zions Bancorporation, National Association (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) from $52 to $55. Baird analyst David George maintained a Neutral rating. Zions Bancorporation shares closed at $49.44 on Monday. <a href="https://www.benzinga.com/quote/ZION/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank raised FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) price target from $125 to $160. Deutsche Bank analyst Hillary Cacanando maintained a Buy rating. FTAI Aviation shares settled at $142.36 on Monday. <a href="https://www.benzinga.com/quote/FTAI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies boosted Paylocity Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) price target from $145 to $200. Jefferies analyst Samad Samana upgraded the stock from Hold to Buy. Paylocity Holding shares closed at $171.45 on Monday. <a href="https://www.benzinga.com/quote/PCTY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho cut Churchill Downs Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) price target from $157 to $151. Mizuho analyst Ben Chaiken maintained an Outperform rating. Churchill Downs shares closed at $135.49 on Monday. <a href="https://www.benzinga.com/quote/CHDN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital raised the price target for Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) from $240 to $255. BMO Capital analyst Ari Klein maintained a Market Perform rating. Marriott shares settled at $264.97 on Monday. <a href="https://www.benzinga.com/quote/MAR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group raised Ferrari N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>) price target from $475 to $565. Evercore ISI Group analyst Michael Binetti maintained an Outperform rating. Ferrari shares closed at $480.18 on Monday. <a href="https://www.benzinga.com/quote/RACE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen cut the price target for Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) from $16 to $14. TD Cowen analyst Charles Ryhee maintained a Buy rating. Walgreens shares closed at $10.45 on Monday. <a href="https://www.benzinga.com/quote/WBA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup boosted First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) price target from $200 to $254. Citigroup analyst Vikram Bagri upgraded the stock from Neutral to Buy. First Solar shares closed at $196.25 on Monday. <a href="https://www.benzinga.com/quote/FSLR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying RACE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22092927/image-202-1024x499.png" alt="" class="wp-image-607431" style="width:597px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22092927/image-202-1024x499.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22092927/image-202-300x146.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22092927/image-202-768x374.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22092927/image-202.png 1327w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41429862/this-analyst-with-85-accuracy-rate-sees-around-11-upside-in-netflix-here-are-5-stock-picks-for-last">This Analyst With 85% Accuracy Rate Sees Around 11% Upside In Netflix &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

CHDN

FSLR

FTAI

PCTY

RACE

ZION

Ferrari To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday

TD Cowen analyst Charles Ryhee maintains Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) with a Buy and lowers the price target from $16 to $14.

TD Cowen Maintains Buy on Walgreens Boots Alliance, Lowers Price Target to $14

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>). &#8220;It can make money even at these<a href="https://www.benzinga.com/quote/CTRA"> levels,&#8221; he noted</a>.
On Oct. 10, Scotiabank analyst Paul Cheng maintained Coterra Energy with a Sector Outperform and lowered the price target from $35 to $32.
&#8220;It trades with the whole group, and the group is actually trading very, very well,&#8221; Cramer said when asked about Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>). &#8220;You're in good shape with ET.&#8221;
Energy Transfer will release earnings for the third quarter on Wednesday, Nov. 6, after the closing bell.
&#8220;Tim Wentworth [CEO of Walgreens] is really an excellent CEO. The bad news is you're up against Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>),&#8221; Cramer said when asked about Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>). &#8220;I'm a a believer in Tim, I really hope it works. But that is a one tough spot he's got himself in.&#8221;
On Oct. 15, Walgreens reported fourth-quarter fiscal year 2024 sales of $37.55 billion, up 6% year over year (+6.1% on constant currency), beating the consensus of $35.76 billion, reflecting sales growth <a href="https://www.benzinga.com/news/earnings/24/10/41333092/walgreens-boots-alliance-outlines-three-cost-saving-strategy-as-q4-earnings-beat-street-estimates">across all segments</a>.
The &#8220;Mad Money&#8221; host said it's going to be a good quarter for Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>). &#8220;It's in the data center, that's why we like it,&#8221; he added.
On Oct. 17, Mizuho analyst Brett Linzey maintained Dover with an Outperform and raised the price target from $200 to $220.
&#8220;This is a very tough situation because all of cosmetics are in a downturn that is so staggering that it caught everybody by surprise,&#8221; Cramer said when asked about e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>).
&#8220;I do think that, when they come back, this one will come back faster than all of them,&#8221; he added.
On Oct. 16, Truist Securities analyst Bill Chappell maintained e.l.f. Beauty with a Buy and lowered the price target from $210 to $130.
Price Action:
<ul>
<li>Energy Transfer shares fell 0.5% to settle at $16.41 on Friday.</li>
<li>Walgreens shares gained 1.2% to close at $10.79.</li>
<li>Coterra Energy shares fell 1.2% to close at $23.78 on Friday.</li>
<li>e.l.f. Beauty shares gained 0.2% to settle at $108.20.</li>
<li>Dover shares fell 0.3% to close at $194.38 on Friday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41421321/dow-s-p-500-settle-at-record-high-levels-record-6th-consecutive-week-of-gains-fear-index-moves-to-e">Dow, S&amp;P 500 Settle At Record High Levels, Record 6th Consecutive Week Of Gains: Fear Index Moves To &#8216;Extreme Greed&#8217; Zone</a></li>
</ul>

Long Ideas

Media

CTRA

Jim Cramer Says This Energy Stock Is A Buy: 'It Can Make Money Even At These Levels'

Whales with a lot of money to spend have taken a noticeably bullish stance on Walgreens Boots Alliance.
Looking at options history for Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 62% of the investors opened trades with bullish expectations and 25% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $113,178 and 6, calls, for a total amount of $254,086.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $5.0 to $12.5 for Walgreens Boots Alliance during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Walgreens Boots Alliance's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Walgreens Boots Alliance's whale activity within a strike price range from $5.0 to $12.5 in the last 30 days. 
<h3>Walgreens Boots Alliance Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729191649_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.55</td>
<td>$0.55</td>
<td>$0.55</td>
<td>$10.00</td>
<td>$82.6K</td>
<td>20.8K</td>
<td>2.2K</td>
</tr>
<tr>
<td>WBA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$0.46</td>
<td>$0.45</td>
<td>$0.45</td>
<td>$10.00</td>
<td>$63.7K</td>
<td>8.1K</td>
<td>3.0K</td>
</tr>
<tr>
<td>WBA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.42</td>
<td>$1.41</td>
<td>$1.42</td>
<td>$10.00</td>
<td>$63.1K</td>
<td>30.9K</td>
<td>1.5K</td>
</tr>
<tr>
<td>WBA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$12.50</td>
<td>$49.4K</td>
<td>10.7K</td>
<td>208</td>
</tr>
<tr>
<td>WBA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$5.9</td>
<td>$5.75</td>
<td>$5.83</td>
<td>$5.00</td>
<td>$29.1K</td>
<td>443</td>
<td>50</td>
</tr>
</tbody>
</table>

<h3>About Walgreens Boots Alliance</h3>
Walgreens Boots Alliance is one of the largest retail pharmacy chains in the US, with over 8,000 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the US. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.
<h3>Walgreens Boots Alliance's Current Market Status</h3>
<ul>
<li>With a volume of 23,197,113, the price of WBA is down -0.9% at $10.97. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<h3>What The Experts Say On Walgreens Boots Alliance</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $9.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Underweight rating on Walgreens Boots Alliance with a target price of $8. 
&#x2A; An analyst from UBS persists with their Neutral rating on Walgreens Boots Alliance, maintaining a target price of $10. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Underweight rating on Walgreens Boots Alliance, which currently sits at a price target of $7. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Walgreens Boots Alliance, targeting a price of $10. 
&#x2A; An analyst from Evercore ISI Group persists with their In-Line rating on Walgreens Boots Alliance, maintaining a target price of $10. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Walgreens Boots Alliance with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

What the Options Market Tells Us About Walgreens Boots Alliance

Realty Income Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/o#NYSE">O</a>), known as &quot;The Monthly Dividend Company,&quot; is a Real Estate Investment Trust (REIT) with a unique approach to commercial real estate. Unlike many of its peers, Realty Income focuses exclusively on free-standing properties, securing them under long-term net lease agreements.&nbsp;
This strategy provides investors with a dependable stream of passive income generated by a diversified portfolio of high-quality tenants. This business model, combined with a commitment to consistent dividend payouts and strategic acquisitions, has fueled Realty Income&#39;s impressive growth and positioned it as a favorite among investors seeking reliable income and long-term growth potential.
<h2>The Triple-Net Lease Advantage</h2>
Realty Income&#39;s triple-net lease model is a cornerstone of its business strategy, further reinforcing the company&#39;s commitment to efficient operations and predictable cash flows. This model, where tenants shoulder the responsibility for property taxes, maintenance, and utilities, minimizes Realty Income&#39;s operational expenses, making it easier to forecast earnings and plan for future dividend payments.&nbsp;
This structure also offers tenants significant flexibility, allowing them to focus on their core business operations while securing long-term occupancy of their facilities. For example, Realty Income&#39;s portfolio includes properties leased to a diverse range of tenants, from national retailers like Walgreens (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wba#NASDAQ">WBA</a>) and Dollar General (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dg#NYSE">DG</a>) to regional and local businesses. This strategy has enabled Realty Income to generate a steady stream of passive income, which has fueled its consistent dividend payments and impressive long-term growth.
<h2>The Monthly Dividend Advantage</h2>
Realty Income is known as &quot;The Monthly Dividend Company,&quot;&nbsp; representing its commitment to paying consistent dividends every month.
This approach has differentiated the company in the REIT market, appealing to investors who prefer a regular, steady income stream.
Since its initial public offering (IPO) in 1994, Realty Income has consistently increased its dividend payment 127 times, a testament to its commitment to shareholder value.
Realty Income&#39;s dividend history has solidified its reputation as a reliable income source, drawing investors seeking dependable and growing dividend income.
<h2>Realty Income&#39;s Growth and Financial Performance</h2>
Realty Income&#39;s earnings report for the second quarter of 2024 underscores its ability to deliver consistent growth. Realty Income reported earnings per share (EPS) of $0.29, slightly missing analysts&#39; consensus estimates of $0.36. However, it&#39;s crucial to look at the bigger picture. While the EPS did not meet Realty Income&#39;s analyst community&#39;s expectations, the company&#39;s revenue reached $1.34 billion, representing a robust 31.4% increase year-over-year. This solid revenue growth reflects Realty Income&#39;s ability to acquire high-quality properties and maintain consistent occupancy rates.
This recent performance also saw Realty Income declare a monthly dividend increase, raising the payment to $0.2635 per share from $0.2630 per share. This increase, representing an annualized dividend amount of $3.162 per share, further highlights the company&#39;s commitment to rewarding its shareholders with growing dividend income.
<h2>Realty Income&#39;s Diversification Strategy</h2>
Realty Income&#39;s diversification strategy is a key factor in its long-term growth. The company has expanded its portfolio to include properties in the US, UK, and Spain, spreading its geographic reach and mitigating risk. This proactive risk management offers several advantages for investors, reducing portfolio volatility and increasing returns. By diversifying across multiple markets, Realty Income is better positioned to withstand potential economic downturns and maintain steady growth regardless of local market conditions.
<h2>Realty Income&#39;s Secret Sauce</h2>
Realty Income&#39;s success is driven by a combination of factors that give the company a significant competitive advantage. The company&#39;s focus on triple-net leases minimizes its operational expenses, providing a more predictable cash flow for investors. Realty Income&#39;s diversification strategy, extending its reach across industries and geographies, further enhances its ability to weather economic fluctuations.
Furthermore, Realty Income&#39;s strong balance sheet and deep industry experience allow it to attract high-quality tenants. These tenants are willing to commit to long-term lease agreements, providing the company with a steady stream of rental income that supports its consistent dividend payments.
<h2>Strategies for Different Investors</h2>
Investing in Realty Income requires careful consideration of personal investment goals and risk tolerance. While the company is attractive to a wide range of investors, two primary strategies stand out for different investor profiles:
<h3>Income-Focused Investors</h3>
Realty Income is an attractive option for those seeking a dependable stream of dividend income. The company&#39;s commitment to shareholder value and history of consistent dividend payments, including a track record of 652 consecutive monthly dividend payments, make it a strong contender for investors seeking a reliable source of income. This consistent payout, combined with its triple-net lease model, which minimizes operating expenses for Realty Income, creates a stable and predictable cash flow stream that supports these dividends.
<h3>Growth-Oriented Investors</h3>
While Realty Income&#39;s primary focus is on dividends, the company has also demonstrated consistent growth in its portfolio and share price. Growth-oriented investors can consider Realty Income as a core holding within a diversified portfolio. The company&#39;s strategic acquisitions, expansion into new markets, and strong tenant relationships provide a solid foundation for continued growth, offering investors the potential for income and capital appreciation. Realty Income&#39;s global diversification strategy, with a presence in the US, UK, and Spain, further mitigates risk and creates opportunities for growth in various markets.
Realty Income has carved a unique niche in the REIT sector by focusing on triple-net leases and offering investors dependable monthly dividend payments. The company&#39;s consistent growth, diversification strategy, and competitive advantages have solidified its reputation as a reliable income source. Investors seeking a dependable dividend stream and potential for long-term growth may find Realty Income an attractive investment opportunity.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/realty-income-a-dividend-powerhouse-with-growth-potential/">Realty Income: A Dividend Powerhouse With Growth Potential</a>&quot; first appeared on MarketBeat.

Earnings

Mid Cap

REIT

Offerings

IPOs

Real Estate

Realty Income: A Dividend Powerhouse With Growth Potential

UBS analyst Kevin Caliendo maintains Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) with a Neutral and raises the price target from $9 to $10.

UBS Maintains Neutral on Walgreens Boots Alliance, Raises Price Target to $10

Barclays analyst Steve Valiquette maintains Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) with a Underweight and raises the price target from $7 to $8.

Barclays Maintains Underweight on Walgreens Boots Alliance, Raises Price Target to $8

Every once in a while, a major brand name and its stock&#39;s existence are challenged. Often, the price action and the threatening state of the company are justified, and the business does end up going under. Other times, this is not the case, and investors can catch a life-changing rally in their portfolios. Today, one stock offers investors such an opportunity.
It can be found in shares of healthcare sector retailer&nbsp;Walgreens Boots Alliance Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wba#NASDAQ">WBA</a>) now that they trade at only 33% of its 52-week high, which is where investors can begin to build a potential bull case carrying double-digit upside in the coming quarters, though there could be a catalyst to bring a rally much sooner than most out there think, particularly the bears.
The last time a stock was threatened to be de-listed due to falling fundamentals, the stock went on to a more than tenfold increase in only a few quarters. That stock was Carvana Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvna#NYSE">CVNA</a>) from early 2023 until today, as the company rallied from $7 a share to more than $192 in today&#39;s market. The key is management making the right moves, and just like Carvana, Walgreens could be about to make it as well.
<h2>Investors Bet on Walgreens Stock Surge Ahead of Anticipated Major Announcement</h2>
It&#39;s not as clear yet, but management is making a major shift ahead of its new quarterly earnings announcement this week. Realizing that the brick-and-mortar business model is not paying off anymore, management decided to start closing down some of its underperforming locations.
Now, while this will clear up some overhead costs and lease debt, helping margins and the bottom line, it will also potentially hurt Walgreens&#39; ability to generate revenue moving forward. At least, that is what bearish traders are betting on as they brought the stock&#39;s short interest up to 13.3% of the entire share float.
These bears might be in for some pain, however, as Walgreens has announced double-digit growth in its digital products segment through Shields and VillageMD subscription-based business. As digital businesses, these segments will expand Walgreens&#39; margins and earnings to offset some of today&#39;s physical location headwinds.
Another benefit is decreased capital expenditure needs, as fewer physical locations need less inventory on hand and fewer overhead expenses, clearing up more cash flow for the company to focus on more productive investments.
These are some of the more obvious announcements that management can make this week, aiding a more optimistic future in the coming quarters, but there is also one more pending thesis out there. Walgreens is now offering shareholders a dividend yield of 10.9% today, taking away over $1 billion in cash flows that could be used to revitalize the business.
Cutting this dividend might not seem positive, but it is the right choice, however tough. Even with the low likelihood of this happening, Wall Street analysts are beginning to reflect a more optimistic outlook for the stock through their recent price targets.
<h2>Wall Street Signals Potential Rally for Walgreens Stock</h2>
Analysts&#39; consensus price target on Walgreens stock is $13.5 a share, calling for up to 46.1% upside from today&#39;s price. However, investors should focus on the outlier ratings that have come in during recent months so that sentiment can be further gauged for the company.
Those at TD Cowen reiterated their Buy rating on Walgreens stock, this time coupling their view with a price target of up to $16 a share, which implies a significantly bigger upside of 74% from today&#39;s stock price. This further reiterates the potential rally inherent in Walgreens stock for the coming months, but there&#39;s more evidence to consider.
Others on Wall Street shared analyst enthusiasm for Walgreens stock. Allocators like Compagnie Lombard Odier boosted their holdings in the stock by 33.2% as of October 2024, bringing their position to a net $119,000 ahead of the earnings announcement.
Ultimately, investors can check the options activity for more precise bets being made in Walgreens stock. As of today, the options chain shows the highest open interest is set for $10 call options expiring only two days after the company announces its earnings report.
With up to 22,056 contracts open for this strike price and expiration, investors can safely assume that traders have a good idea of what could be coming to Walgreens stock this week, something to consider before the stock potentially becomes another Carvana run.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/double-digit-rally-coming-for-walgreens-stock-time-to-jump-in/">Big Potential Brewing &ndash; Will Walgreens Deliver a Rally?</a>&quot; first appeared on MarketBeat.

Contracts

Retail Sales

Management

CVNA

Big Potential Brewing – Will Walgreens Deliver a Rally?

Walgreens Boots Alliance Inc (NASDAQ: WBA) reported fourth-quarter fiscal year 2024 sales of $37.55 billion on Tuesday. 
That&#8217;s up 6% year over year (+6.1% on constant currency). The numbers beat the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $35.76 billion</a>, reflecting sales growth across all segments.
Walgreens Boots Alliance announced a footprint optimization program targeting approximately 1,200 closures over the next three years. This includes approximately 500 closures in fiscal 2025, which will be immediately accretive to adjusted <a href="https://www.benzinga.com/news/earnings/24/10/41333092/walgreens-boots-alliance-outlines-three-cost-saving-strategy-as-q4-earnings-beat-street-estimates" target="_blank" rel="noreferrer noopener">EPS and free cash flow</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41279374/cvs-health-positioned-for-medicare-margin-expansion-and-market-share-gains-says-bar" rel="noreferrer noopener">CVS Health Positioned For Medicare Margin Expansion And Market Share Gains, Says Barclays Analyst</a>.
The company said it exceeded fiscal 2024 targets for&nbsp;$1 billion&nbsp;in cost savings,&nbsp;a $600 million&nbsp;reduction in capital expenditures, and&nbsp;$500 million&nbsp;in working capital initiatives.
Truist Securities noted that Walgreens Boots Alliance finished the fiscal year 2024 on a strong note, meeting management&#8217;s expectations and exceeding projections for both revenue and earnings.
The fiscal 2025 guidance reflects optimism, aligning with the higher end of Truist Securities&#8217; and consensus forecasts.
Both international and U.S. healthcare segments delivered solid performances despite ongoing challenges in consumer spending and pharmacy reimbursement pressures. However, the outlook on reimbursement was positive. Fourth-quarter cash flow surpassed expectations and remains a critical focus, while capital expenditures and working capital improvements are encouraging.
Truist <a target="_blank" href="https://www.benzinga.com/quote/WBA/analyst-ratings" rel="noreferrer noopener">maintains the Hold rating</a>, with a price target of $10.
RBC Capital notes that Walgreens Boots Alliance has outlined its planned store closures through 2027, offering greater clarity and reducing the uncertainty around the higher end of potential closures.
The analyst also highlights that Walgreens is investing in locations it anticipates will absorb prescriptions and foot traffic from the closing stores. 
Having already shuttered a few hundred locations in fiscal year 2024, the company has recent experience managing patient transitions and prescription volumes.
Evercore ISI maintains Walgreens Boots Alliance with an In-Line rating and raises the price target from $7.5 to $10.
Price Action: WBA stock is up 4.32% at $10.87 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41362705/sofi-boosts-payment-services-with-galileos-cloud-based-cyberbank-core" target="_blank" rel="noreferrer noopener">SoFi Boosts Payment Services with Galileo&#8217;s Cloud-Based Cyberbank Core</a>.</li>
</ul>
Image: Shutterstock

Analyst Color

Walgreens Boots Alliance Analysts Expect Strategic Plans Will Boost Investor Confidence In 2025

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
<h3 class="wp-block-heading">Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)</h3>
<ul>
<li>Dividend Yield: 9.16%</li>
<li>Morgan Stanley analyst Erin Wright maintained an Underweight rating and cut the price target from $9 to $7 on Oct. 11. This analyst has an accuracy rate of 75%.</li>
<li>Truist Securities analyst David Macdonald maintained a Hold rating and cut the price target from $13 to $10 on Oct. 7. This analyst has an accuracy rate of 74%</li>
<li>Recent News: On Tuesday, Walgreens reported fourth-quarter fiscal year 2024 sales of $37.55 billion, up 6% year over year (+6.1% on constant currency), beating the consensus of $35.76 billion, reflecting sales growth across all segments.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1">latest WBA news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="913" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143111/image-127.png" alt="" class="wp-image-599050" style="width:538px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143111/image-127.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143111/image-127-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143111/image-127-768x707.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure>
<h3 class="wp-block-heading">Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>)</h3>
<ul>
<li>Dividend Yield: 4.73%</li>
<li>B of A Securities analyst Bryan Spillane maintained a Neutral rating and cut the price target from $34 to $33 on Oct. 3. This analyst has an accuracy rate of 65%.</li>
<li>Evercore ISI Group analyst David Palmer maintained a Neutral rating and lowered the price target from $32 to $31 on July 12. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: On Oct. 2, ConAgra Brands reported worse-than-expected first-quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted t<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1">o latest CAG news.</a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="903" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143147/image-128.png" alt="" class="wp-image-599053" style="width:648px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143147/image-128.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143147/image-128-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143147/image-128-768x710.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<h3 class="wp-block-heading">Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>)</h3>
<ul>
<li>Dividend Yield: 4.47%</li>
<li>Goldman Sachs analyst Bonnie Herzog maintained a Buy rating and raised the price target from $126 to $140 on Sept. 26. This analyst has an accuracy rate of 69%.</li>
<li>Barclays analyst Gaurav Jain maintained an Overweight rating and boosted the price target from $130 to $145 on Sept. 9. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: Philip Morris will host a live audio webcast on Tuesday, Oct. 22 to discuss its third-quarter results.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1">trend in PM stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143219/image-129.png" alt="" class="wp-image-599056" style="width:696px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143219/image-129.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143219/image-129-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143219/image-129-768x716.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h">United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday</a></li>
</ul>

Wall Street's Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields

Evercore ISI Group analyst Elizabeth Anderson maintains Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) with a In-Line and raises the price target from $7.5 to $10.

Evercore ISI Group Maintains In-Line on Walgreens Boots Alliance, Raises Price Target to $10

This week, several dividend stocks are trading close to their 52-week lows. Here is a list of ten such stocks that are also reaching their ex-divid...

Ex-Dividend Date Nearing for These 10 Stocks – Week of November 18, 2024

Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here's an updated look at the top 10 worst performing large-caps, along with their one-year price returns.

Large-Cap Stocks In Trouble - Sunday, Nov. 17

Walgreens: 11.9% Dividend Yield Still On Unsteady Legs

Beware Juicy Yields And ETF Expense Ratios

Walgreens: Profits In Free-Fall, No Cure In Sight

Bad News For Realty Income

My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys

Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC

Large-Cap Stocks In Trouble - Saturday, Nov. 23

Evercore ISI analyst Elizabeth Anderson CFA maintained a Hold rating on Walgreens Boots Alliance (WBA – Research Report) today and set a price targ...

Evercore ISI Remains a Hold on Walgreens Boots Alliance (WBA)

AAPL

ABBV

AGNC

AGNCL

AGNCM

AGNCN

AGNCO

AGNCP

ALHC

ALIZF

AMGN

APTV

ARCC

AVGO

BABA

BASFY

BAYZF

BIIB

BLUE

BXSL

CBAUF

CLOV

CSCO

CSWC

DGRO

DLTR

DXCM

GAIN

GILD

GLAD

GOOD

GSBD

HTGC

INTC

KELYA

MAIN

MCHP

MFIC

MRNA

MSFT

NEWT

NVDA

OBDC

RITM

RWAY

SACH

SCHD

SEMHF

SHEL

SNYNF

STAG

STNG

STWD

UNIT

Press Releases

Walgreens Boots Alliance Reports Fiscal Year 2024 Earnings

Walgreens Collects More than 6-Million Pounds of Unused Prescription Medication, Seeks the Public's Help for National Drug Takeback Day

Walgreens and Dion's Chicago Dream Join Forces to Host a Dream Vault Smart Locker in Gage Park Store

Walgreens and Veeva Form Strategic Partnership

Walgreens Boots Alliance Declares Quarterly Dividend

Uber Eats Now Accepting SNAP EBT Nationwide With Albertsons Companies, Walgreens

Walgreens Honors Veterans, Active Duty Military and Families with Veterans Day Discount Friday, November 8 through Monday, November 11

Walgreens Launches Annual Flu Index to Help Communities Track Flu Activity

Walgreens Offers No-Cost Rapid COVID-19 and Flu Testing to Military Veterans

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare

Comments

Walgreens Boots Alliance

Intérêt court

Walgreens Boots Alliance (NASDAQ:WBA) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL